Board summary
Key figures
52,022
Registered population
58.8% aged 18–64
21.4%
Aged 65+
ICB 18.8% · England 17.9%
20.9%
Ethnic minority (non-White)
12.4% Asian · England 9.6%
0.0%
In IMD quintile 1
ICB 0.8% · England 21.0%
0
Core20 residents (est.)
Resident basis; registered basis 0 · see page 3
8,958
Hypertension register
+4.11% in 3 yrs · England +5.60%
420
SMI register
47.2% of Spelthorne's
854
COPD register
Reviews +5.67% in 3 yrs
Forecast to 2030
10,270
Hypertension patients, 2030
+1,312 on today
69.6%
QRISK ≥20% on statins, 2030
+4.35pp over 3 yrs
5.9%
Cancer prevalence, 2030
England 4.5%
Three things the board should see
Pre-school booster coverage drops at age five.
Age-5 MMR coverage drops 7 pp from 96.2% (dose 1) to 89.2% (dose 2), with 4-in-1 at 87.7%, below the 95.0% target.
Lipid therapy lags alongside higher unit costs.
QRISK >= 20% lipid therapy is 59.9% (England 63.6%), while lipid-modifying items cost £2.70 (£60,620 more than at England's £1.86 unit cost).
Hypertension blood pressure control exceeds comparator benchmarks.
Among hypertension patients, 90.2% have a recent blood pressure reading and 72.4% are treated to target, above Spelthorne (69.5%) and England (70.3%).
Population, age and ethnicity
Older age profile and concentrated borough inclusion health caseloads shape local primary care
Across 52,022 registered patients, 21.4% (11,154 patients) are aged 65+, above Spelthorne (17.4%), the ICB (18.8%) and England (17.9%). Working-age adults (18-64) comprise 58.8% and children (0-17) 19.8%. Projected list growth to 2030 is 5.6%, matching Spelthorne (5.6%) and above the ICB (4.9%) and England (2.3%), though projection methodology is unverified. In associated areas, 20.9% of usual residents are from ethnic minorities, with 12.4% Asian or Asian British (Spelthorne 12.8%, ICB 7.7%, England 9.6%) and 79.1% White. Census resident ethnicity does not reflect registered-patient ethnicity.
Age profile
65+: ICB 18.8%, England 17.9%
Ethnicity
Older people · falls rows are Spelthorne local-authority (LA) data, not PCN
| Measure | Local | South East | England | Period |
|---|---|---|---|---|
| Falls admissions, 65+, per 100,000 (Spelthorne LA) | 1,875 | 2,018 | 1,958 | 2024/25 |
| Diabetes with frailty: HbA1c ≤75 mmol/mol (PCN) | 80.1% | 82.2% | 81.9% | 2024/25 |
| Diabetes without frailty: HbA1c ≤58 mmol/mol (PCN) | 58.1% | 57.8% | 57.4% | 2024/25 |
| Falls admissions, 65 to 79, per 100,000 (Spelthorne LA) | 950 | 981 | 955 | 2024/25 |
| Falls deaths, all ages, per 100,000 (Spelthorne LA) | 10.7 | 14.0 | 14.8 | 2022‑24 |
Deprivation and Core20
Core20 registered population is 0.0% PCN-wide, alongside an average IMD decile of 6.9
The PCN average IMD decile is 6.9, above Spelthorne (6.5) and England (5.5), and below NHS Surrey Heartlands Integrated Care Board (7.9). The registered Core20 cohort is 0.0%, below Spelthorne (1.8%), NHS Surrey Heartlands Integrated Care Board (0.8%), and England (21.0%). Practice Core20 rates reconcile at 0.0% across all four practices (0 estimated Core20 patients), with average IMD deciles spanning from 6.1 at Studholme Medical Centre to 7.4 at Shepperton Medical Practice. With zero Core20 residents, area deprivation metrics do not capture local health inequalities, requiring individual clinical risk identification.
% of patients in IMD quintile 1, by practice
Dashed line: England 21.0% · right column: Core20 patients, registered basis
PLUS groups and inclusion health
PLUS groups and inclusion health
420
SMI register
0.81% recorded prevalence
186
Learning disability register
0.36% recorded prevalence
12
Care homes, 557 beds
In the PCN catchment
8.6%
Provide unpaid care
Spelthorne, Census 2021
The PCN records 420 patients on its severe mental illness register and 186 on its learning disability register, comprising 47.2% and 48.3% of Spelthorne's borough totals. Catchment sites include 12 care homes with 557 beds. Concentrated borough inclusion health registers indicate substantial tailored physical health check and care home coordination needs across the network.
Severe mental illness: physical health checks
On the 420-patient severe mental illness register, BMI recording is 86.9% (England 82.1%), while 3-year blood pressure check growth of +2.7 pp trails England (+4.4 pp) and alcohol recording is 79.2% (England 81.8%).
Clinical focus: hypertension and lipids
Clinical focus: hypertension and lipids
8,958
Hypertension register
+4.11%
Register growth, 3 yrs
Spelthorne +4.33% · England +5.60%
+3.62pp
BP control, under 80
≤140/90 · +1.70pp aged 80+
+1,312
More patients by 2030
Forecast 10,270 (18.65%)
Hypertension case-finding and control
Recorded hypertension prevalence is 17.2% (8,958 patients), above Spelthorne (15.7%), NHS Surrey Heartlands Integrated Care Board (14.3%) and England (15.2%). Among registered patients, 90.2% have a recent blood pressure reading (England 90.0%) and 72.4% are treated to target (England 70.3%). Three-year register growth of +4.1% trails England (+5.6%) and the ICB (+5.3%). Practice prevalence spans from 15.2% at Upper Halliford Medical Centre to 19.6% at Shepperton Medical Practice. Crude prevalence differences do not establish undiagnosed disease, and the unverified 2030 projection of 10,270 patients is for planning scale only.
Lipids and statins
At 59.9%, lipid-lowering therapy for patients with QRISK ≥ 20% trails Spelthorne (61.7%) and England (63.6%), though it exceeds NHS Surrey Heartlands Integrated Care Board (59.4%). Statin treatment in diabetes with cardiovascular disease is 82.8% (England 84.4%).
| Measure | Items | Cost / item | ICB | England | Annual spend |
|---|---|---|---|---|---|
| Lipid-modifying, 2026 | 72,167 | £2.70 | £2.24 | £1.86 | £194,851 |
| Cardiovascular (all), 2025 | 102,902 | £5.45 | £4.74 | £3.33 | £560,816 |
In 2026, the PCN prescribed 72,167 lipid-modifying items at £2.70 per item, above Spelthorne (£2.36), NHS Surrey Heartlands Integrated Care Board (£2.24) and England (£1.86). This unit cost is £60,620 more than at England's unit cost, across 72,167 items.
Clinical focus: respiratory, cancer register and children
Clinical focus: respiratory, cancer register and children
Respiratory
+1.06%
Asthma reviews, PCN 3-yr % change
+4.44%
Asthma reviews, England 3-yr % change
+4.54%
Asthma prevalence, PCN 3-yr % change
Across 854 registered patients, COPD annual reviews reach 82.9% (England 76.4%, Spelthorne 85.9%) with 3-year growth of +5.7% (England +2.8%). Asthma reviews reach 68.0% across 2,912 registered patients (Spelthorne 70.6%), with 3-year growth of +1.1% (England +4.4%), leaving about 930 patients (931) unreviewed. Asthma management items prescribed per 1000 5-19 Population is 917 rate (England 1,488 rate).
Cancer register and children's immunisation
The cancer register records 2,588 patients (5.0%, England 3.8%). At age 5, MMR dose 1 coverage is 96.2%, exceeding the 95.0% target. MMR dose 2 coverage is 89.2%, trailing dose 1 by 7 pp and falling 5.8 pp below the 95.0% target. Coverage for the 4-in-1 pre-school booster is 87.7%, 7.3 pp below the 95.0% target.
Dashed line: 95% national coverage target · solid tick: England
Early cancer diagnosis
Early cancer diagnosis
61.4%
Surrey Heartlands ICB, stage 1–2
55.3%
England, 2022
75%
National ambition by 2028
~650
Extra early-stage cases a year to reach the ambition
| Stage 1–2 share by cancer type, 2022 | Surrey Heartlands ICB | England | No usable stage | Staged cancers |
|---|---|---|---|---|
| Prostate | 65.7% | 53.2% | 18% | 1,044 |
| Breast | 88.2% | 85.4% | 27% | 798 |
| Bowel | 48.1% | 47.0% | 18% | 626 |
| Lung | 33.2% | 33.8% | 17% | 497 |
| Skin cancer | 89.8% | 87.8% | 19% | 384 |
Across NHS Surrey Heartlands ICB in 2022, 61.4% of cancers with a known stage (2,955 of 4,810) were diagnosed at stage 1 or 2, above England (55.3%) but 13.6 percentage points below the 75.0% national ambition (about 650 additional cases needed; tumour cohorts vary). Known-stage coverage was 67.7% (4,810 of 7,106 registered cancers), describing wider system staging rather than PCN performance. Locally, cervical screening aged 25-49 is 70.8% (England 66.8%) but fell 2.8% over three years (England -1.0%), trailing at Upper Halliford Medical Centre (65.8%).
Cancer waits, diagnostics and community services
Cancer waits, diagnostics and community services
Cancer waits and diagnostics, Jul 2026 (provisional)
At Ashford and St Peter's Hospitals NHS Foundation Trust in July 2026 (provisional), the 62-day referral to treatment standard reached 76.4%, above England (71.2%) and NHS Surrey and Sussex Integrated Care Board (71.5%), but 8.6 percentage points below the 85.0% standard. The 28-day faster diagnosis standard achieved 85.5% (England 79.3%). Diagnostic delays remain concentrated in endoscopy, with 49.6% waiting 6+ weeks for colonoscopy and 57.9% for flexi sigmoidoscopy (England 30.8% and 32.1%), whereas MRI waits of 6+ weeks were 0.1% (England 21.4%). These provider-level figures describe system diagnostic waits rather than PCN pathway management.
| Pathways within standard (%) | Ashford and St Peter's | Chelsea and Westminster | Kingston and Richmond | Surrey and Sussex ICB | England |
|---|---|---|---|---|---|
| 28-day faster diagnosis (75%) | 85.53 | 83.22 | 80.07 | 79.29 | 79.32 |
| 31-day treatment (96%) | 94.21 | 97.60 | 98.77 | 90.45 | 92.50 |
| 62-day referral to treatment (85%) | 76.38 | 90.41 | 75.32 | 71.51 | 71.16 |
| Diagnostic waits over 6 weeks (%) | Ashford and St Peter's | Chelsea and Westminster | Kingston and Richmond | England |
|---|---|---|---|---|
| MRI | 0.09 | 8.15 | 0.19 | 21.40 |
| CT | 9.27 | 24.36 | 0.00 | 9.92 |
| Echocardiography | 0.97 | 22.93 | 4.89 | 28.48 |
| Colonoscopy | 49.61 | 7.04 | 70.17 | 30.83 |
| Gastroscopy | 56.74 | 2.20 | 79.18 | 29.02 |
| All 15 DM01 tests | 23.12 | 18.61 | 31.56 | 23.14 |
| Community services activity | Surrey residents | Surrey and Sussex ICB |
|---|---|---|
| Care contacts | 109,530 | 309,615 |
| Referrals | 28,700 | 66,930 |
| Patients with a contact | 33,510 | 85,660 |
Community services (residents of Surrey), Jun 2026 (provisional). In the Community Services Dataset for June 2026 (provisional), 69.6% of community contacts with Spelthorne residents (76,215 of 109,530) were for adults aged 65+. These borough-level figures reflect wider system engagement among older cohorts rather than PCN-specific intermediate care delivery.
Practice variation and patient experience
Patient phone access spans 19.5 percentage points across the PCN's four practices
GP Patient Survey by practice
| Practice | Responses | % in IMD Q1 | Phone easy | Request led to appt | Overall good |
|---|---|---|---|---|---|
| Shepperton | 122 | 0.0 | 45.1% | 71.9% | 85.2% |
| Sunbury | 109 | 0.0 | 55.9% | 78.1% | 75.6% |
| Upper Halliford | 131 | 0.0 | 39.6% | 61.8% | 68.3% |
| Studholme | 91 | 0.0 | 36.4% | 76.6% | 63.5% |
| England | — | ~21 | 56.9% | 71.6% | 76.7% |
Where the PCN lags
Twelve of 25 measures trailed England's three-year change, led by heart failure reviews
Twelve of 25 tracked measures trailed England over three years. The widest relative lags were heart failure reviews (-3.8% vs +8.7% England, trailing by 12.5 points; current level 74.2% vs 78.5%) and breast screening (+2.8% vs +8.4% England, trailing by 5.6 points). Conversely, the network outperformed England in severe mental illness BMI recording (+8.1 pp vs +5.1 pp England), COPD reviews (+5.7% vs +2.8% England), and under-80 blood pressure control (+5.5% vs +3.2% England).
3-year change · PCN vs England
Bars show the direction and scale of relative change. Orange: PCN · Grey: England.
Heart failure reviews
Breast screening (53-70)
Asthma reviews
Cervical screening
Diabetes HbA1c control
BMI record (SMI)
COPD reviews
BP control, under 80
What the data can't tell us: gaps and local assets
What the data can't tell us: gaps and local assets
| Local assets and voluntary sector | PCN | Spelthorne | Asset | PCN | Spelthorne |
|---|---|---|---|---|---|
| Care homes (catchment) | 12 (557 beds) | n/a | Schools (catchment) | 53 | n/a |
| Children's centres | 5 | 6 | Places of worship | 28 | 43 |
| Libraries | 1 | 1 | Homelessness support (VCS) | 0 | no data |
| Day centres (VCS) | n/a | 1 | Carers support groups (VCS) | n/a | 1 |
| Primary schools (LA maintained) | 8 | 8 | Primary academies | 6 | 8 |
0 = the source returned zero. n/a = not held at this level. No data = no value returned; this does not mean zero.
Options for the PCN
Options for the PCN
Each option in full
Option 1
Pre-school booster and MMR2 catch-up
At age 5 (130 children), MMR1 is 96.2% while MMR2 is 89.2% (7 pp lower; 5.8 pp below the 95.0% target) and 4-in-1 is 87.7% (7.3 pp below target). For discussion: practices could audit age-5 cohorts for overdue MMR2 and 4-in-1 doses and test flexible catch-up clinics. Low cost, quick to run.
Evidence base: coverage against the 95% target is the direct measure of programme delivery and catch-up need; where coverage clusters low, that decides whether catch-up is organised at practice, PCN, school or outreach level.
Policy anchor: 10 Year Health Plan, shift from sickness to prevention.
Option 2
Structured asthma annual review recall
Asthma review coverage is 68.0% of the 2,912 register, below Spelthorne (70.6%) with +1.1% 3-year change (England +4.4%), leaving 931 (about 930) unreviewed. For discussion: the PCN could run a single asthma recall template and offer after-school or flexible review slots alongside inhaler checks. Moderate effort to run.
Evidence base: the annual asthma review is the process gap between the register and outcomes.
Policy anchor: Core20PLUS5 chronic respiratory disease priority.
Option 3
Lipid therapy and formulary review
QRISK ≥ 20% lipid therapy is 59.9% (England 63.6%). Across 72,167 lipid-modifying items, unit cost (£2.70 vs £1.86 England) is £60,620 more than England's unit cost. For discussion: clinical pharmacists could audit high-QRISK patients not on lipid-lowering therapy and review lipid-modifying formulary choices. Moderate effort to run.
Evidence base: the hypertension register is the cohort for case-finding, blood-pressure control and AF anticoagulation; its size and growth set the workload those interventions must cover, and a shortfall in control shows up later as emergency admission.
Policy anchor: Core20PLUS5 (hypertension case-finding and optimal management); NHS CVD ambitions to 2029 on detection, treatment to target and statins for high-risk patients (CVDPREVENT).
Provenance and audit trail
Provenance and audit trail
Figures are the profile's, drawn from Coplug indicator tables: census, deprivation and QOF measures, MHCLG, Rough sleeping snapshot in England: autumn 2025, OHID, Fingertips diabetes by frailty status: HbA1c control (93712, 93713) and OHID, Fingertips falls: emergency admissions, 65+ and 65 to 79 (22401, 22402), accidental-fall deaths (94002). Every recommended action and option is the profile's own; the evidence-base statements that support them — what each register is the cohort for, and the national policy it serves — are quoted from Coplug's indicator catalogue. No recommendation in this report is authored outside the profile and that catalogue. ICB- and provider-level data (page 8) describes the system the PCN sits in and is not read as PCN performance.
| Recommendation | Indicator(s) | Policy anchor | Data level |
|---|---|---|---|
| Clinical inclusion health register audit (p3) | Core20 cohort (IMD quintile 1) | Core20PLUS5 · 10YHP equity test | PCN |
| SMI physical health recall audit (p4) | Record of a BP check in the last 12 months for patients on the MH register (denominator incl. PCAs) | MHIS · From Harm to Hope | PCN |
| Hypertension case-finding audit (p5) | Hypertension: QOF prevalence | Core20PLUS5 CVD · CVDPREVENT 2029 | PCN |
| Pre-school booster recall catch-up (p6) | MMR dose 2 coverage at age 5 | 10YHP sickness to prevention · 95% target | PCN |
| Cervical screening recall audit (p7) | Women (25-49 yrs) with a record of cervical screening in the last 3.5 yrs (denominator incl. PCAs) | Fit for the Future: 10 Year Health Plan for England · Medium Term Planning Framework 2026 | PCN |
| Telephony and access review (p9) | GPPS easy to contact the practice by phone | 10YHP, hospital to community | Practice |
| Option 1 · Pre-school booster and MMR2 catch-up (p12) | MMR dose 1 coverage at age 5 · MMR dose 2 coverage at age 5 · 4-in-1 pre-school booster (DTaP/IPV) coverage at age 5 | 10YHP sickness to prevention · 95% target | PCN |
| Option 2 · Structured asthma annual review recall (p12) | Asthma register · Patients with Asthma: review in the last 12 months (denominator incl. PCAs) | Core20PLUS5 respiratory | PCN |
| Option 3 · Lipid therapy and formulary review (p12) | Patients with QRISK ≥ 20% treated with lipid lowering therapy · Cost per item for Lipid-regulating drugs 2026 · Count of Items prescribed for Lipid-regulating drugs 2026 | Core20PLUS5 CVD · CVDPREVENT 2029 | PCN |
Data sources
Data sources
Every figure in this profile comes from a dataset below, at the level and period stated. Nothing published above PCN level is read as PCN performance.
| Dataset | Level | Period | Used for |
|---|---|---|---|
| Coplug indicator tables: census, deprivation and QOF measures | PCN & Practice | 2023 to 2025, projected to 2030; 2023 to 2024 | Pages 1, 2, 3, 4, 5, 6, 7, 8, 10, 12 |
| MHCLG, Rough sleeping snapshot in England: autumn 2025 | Local authority | Autumn 2025 | Pages 2, 4 |
| OHID, Fingertips diabetes by frailty status: HbA1c control (93712, 93713) | PCN | 2024/25 | Pages 2, 4 |
| OHID, Fingertips falls: emergency admissions, 65+ and 65 to 79 (22401, 22402), accidental-fall deaths (94002) | Local authority | 2024/25; 2022-24 | Pages 2, 4 |
| ONS, Census 2021 TS039: provision of unpaid care (age-standardised) | Local authority | Census 2021 | Pages 2, 4 |
| QOF registers, prevalence and care processes (Coplug indicator tables) | Practice | 2023 to 2025, projected to 2030 | Pages 4, 5, 6, 7, 8, 10 |
| UKHSA, COVER supplementary GP data, childhood immunisation coverage, Q1 2025/26 | PCN & Practice | Q1 2025/26 | Pages 4, 6 |
| UKHSA, Seasonal influenza vaccine uptake in GP patients, 2025 to 2026 | ICB | 2025/26 season to 28 Feb 2026 | Pages 4, 6 |
| NHS England, Cancer Waiting Times: July 2026 monthly time series with revisions | ICB & Provider | Jul 2026 (provisional) | Pages 7, 8 |
| NHS England, Community Services Statistics (CSDS): June 2026 provisional experimental data | ICB & Local authority | Jun 2026 (provisional) | Pages 7, 8 |
| NHS England, Monthly Diagnostics Waiting Times and Activity (DM01): provider by test, July 2026 | Provider | Jul 2026 | Pages 7, 8 |
| National Disease Registration Service, Stage at diagnosis by cancer site in England, 2013 to 2022 | ICB | 2022 | Pages 7, 8 |
| NHS England / Ipsos, GP Patient Survey 2026: practice results (weighted) | Practice | Survey Jan-Apr 2026 | Page 9 |
| NHS England, Quality and Outcomes Framework 2025-26: achievement by practice and domain | Practice | 2025/26 | Page 9 |
| NHS England, Quality and Outcomes Framework 2025-26: personalised care adjustments by practice and domain | Practice | 2025/26 | Page 9 |
| Coplug indicator catalogue — definitions, cohorts, policy anchors | Reference | Current | Evidence-base lines, page 13 |
Methods, data-quality notes and limitations
Methods, data-quality notes and limitations
Methods
Estimated gaps apply benchmark prevalence to the registered population and subtract the recorded register. They size the task; they are not confirmed missed patients.
Percentage points are the difference between two rates; a relative change is that difference as a share of the starting rate. Register changes are relative, over three years.
Forecasts to 2030 extend each indicator's current trajectory with no change in case-finding or service model: a baseline to act against, not a prediction.
Core20 is the most deprived 20% nationally (IMD quintile 1). Practice shares are not additive to the PCN figure. Ethnic minority is 100% minus White. Local-authority averages are unweighted.
